3-Benzyloxycarbonylamino-5-(9-fluoro-9H-fluoren-9-ylmethanesulfonylamino)-4-oxo-pentanoic acid | 206198-38-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 3-Benzyloxycarbonylamino-5-(9-fluoro-9H-fluoren-9-ylmethanesulfonylamino)-4-oxo-pentanoic acid
• 英文别名: 5-[(9-Fluorofluoren-9-yl)methylsulfonylamino]-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid
• CAS: 206198-38-1
• 化学式: C₂₇H₂₅FN₂O₇S
• 分子量: 540.569
• InChiKey: QFSJGQAIQKSIJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  38
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  147
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• Sulfonamide interleukin-1beta converting enzyme inhibitors
  申请人：Warner-Lambert Company

  公开号：US20020156094A1

  公开（公告）日：2002-10-24

  The present invention relates to compounds that are inhibitors of interleukin-1&bgr; converting enzyme that have the Formula (I). This invention also relates to a method of treatment of stroke, reperfusion injury, Alzheimer's disease, shigellosis, inflammatory diseases, and septic shock and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1&bgr; converting enzyme.

  本发明涉及一种具有公式（I）的抑制白细胞介素-1β转化酶的化合物。本发明还涉及一种用于治疗中风、再灌注损伤、阿尔茨海默病、志贺菌病、炎症性疾病和感染性休克的方法，以及一种含有抑制白细胞介素-1β转化酶的化合物的药学上可接受的组合物。
• SULFONAMIDE INTERLEUKIN-BETA CONVERTING ENZYME INHIBITORS
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0946502B1

  公开（公告）日：2002-12-18
• METHODS AND COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS
  申请人：BASF AKTIENGESELLSCHAFT

  公开号：EP0998300A1

  公开（公告）日：2000-05-10
• US6316415B1
  申请人：——

  公开号：US6316415B1

  公开（公告）日：2001-11-13
• [EN] SULFONAMIDE INTERLEUKIN-1 beta CONVERTING ENZYME INHIBITORS<br/>[FR] INHIBITEURS DE L'ENZYME DE CONVERSION DE L'INTERLEUKINE 1 beta A BASE DE SULFONAMIDE
  申请人：——

  公开号：WO1998016505A1

  公开（公告）日：1998-04-23

  [EN] The present invention relates to compounds that are inhibitors of interleukin-1 beta converting enzyme that have the Formula (I). This invention also relates to a method of treatment of stroke, reperfusion injury, Alzheimer's disease, shigellosis, inflammatory diseases, and septic shock and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1 beta converting enzyme.
  [FR] L'invention concerne des composés inhibiteurs de l'enzyme de conversion de l'interleukine 1 beta , représentés par la formule (I). L'invention se rapporte également à une méthode de traitement d'ictus, de lésions dues à la reperfusion, de la maladie d'Alzheimer, de la shigellose, de maladies inflammatoires et de chocs septiques, et à une composition pharmaceutiquement acceptable qui contienne un composé inhibiteur de l'enzyme de conversion de l'interleukine 1 beta .